Premium
IL‐10 promoter haplotype influence on interferon treatment response in multiple sclerosis
Author(s) -
Wergeland S.,
Beiske A.,
Nyland H.,
Hovdal H.,
Jensen D.,
Larsen J. P.,
Marøy T. H.,
Smievoll A.I.,
Vedeler C. A.,
Myhr K.M.
Publication year - 2005
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2004.01102.x
Subject(s) - haplotype , multiple sclerosis , medicine , interferon , promoter , immunology , gene , gastroenterology , genotype , gene expression , genetics , biology
The level of interleukin‐10 (IL‐10) expression is related to polymorphisms ‐1082 (G/A), ‐819 (T/C) and ‐592 (A/C) in the promoter region of the IL‐10 gene, which constitute three haplotypes, GCC, ATA, and ACC. The ATA (a non‐GCC) haplotype, which is associated with low IL‐10 expression, has been shown to improve interferon (IFN) treatment response in hepatitis C. We analysed the distribution of IL‐10 promoter haplotype combinations to determine whether they could influence initial IFN treatment response in 63 patients with relapsing‐remitting multiple sclerosis (MS). The patients were grouped into non‐GCC or GCC haplotypes, and the clinical and magnetic resonance imaging (MRI) disease activity was compared in the two groups. During the first 6 months of treatment, MS patients with non‐GCC haplotypes experienced fewer new MRI T1‐contrast enhancing lesions [0.77 ± 0.36 (SEM)] than patients with the GCC haplotype (2.45 ± 0.57) ( P = 0.05, Mann‐Whitney U test). No differences were detected on clinical disease activity. The results suggest an influence of IL‐10 promoter polymorphisms on IFN treatment response in MS.